Vaccines

Vaccines features

• Low levels of innate immune activation and high levels of gut antibodies may protect people from HIV

  Several research papers published in the last month have reported strong correlations between specific immune responses and protection against HIV infection or its effects. These include...

  From:  News

• 

  What about a vaccine?

  There are two ultimate solutions to HIV: a cure and a vaccine. We cover research towards a cure in this issue. But how is the search for...

  From:  HIV treatment update

• 

  Can we create ‘elite controllers’?

  Is combination immunotherapy the future? ask Edwin J Bernard and Derek Thaczuk ...

  From:  HIV treatment update

Vaccines news from aidsmap

• Researchers stop the only current HIV vaccine efficacy trial

  The US National Institute of Allergy and Infectious Diseases (NIAID) has announced that it is discontinuing the HVTN 505 HIV vaccine trial. This trial, which started in July 2009, has involved 2504 gay and transgender volunteers in 19 US cities. ...

  26 April 2013 | Gus Cairns

• Gene therapy studies show potential for HIV control without drugs

  Gene therapy approaches that involve the genetic modification of human haematopoietic stem cells have the potental to engineer HIV control by introducing cells resistant to HIV infection, the 20th Conference on Retroviruses and Opportunistic Infections ...

  13 March 2013 | Gus Cairns

• Low levels of innate immune activation and high levels of gut antibodies may protect people from HIV

  Several research papers published in the last month have reported strong correlations between specific immune responses and protection against HIV infection or its effects. These include a comparison of women in the CAPRISA 004 microbicide trial who became infected and ...

  24 August 2012 | Gus Cairns

• Lower seminal viral load and hints of long-term viral control seen in Thai HIV vaccine recipients

  Men who received the Thai RV144 vaccine who nonetheless became infected with HIV had lower viral loads in their semen than men who received placebo, a new analysis of the vaccine study reports in the Journal of Infectious Diseases.    The report ...

  17 August 2012 | Gus Cairns

• BCG vaccination causes immune activation of CD4 T-cells in infants

  BCG vaccination, routinely given at birth to protect from tuberculosis (TB), causes an immune-activation of CD4 T cells, the HIV target cells, according to a South African study presented at the Nineteenth International AIDS Conference in Washington DC. This immune ...

  31 July 2012 | Lesley Odendal

• Superinfection: second HIV infections happen as often as first ones

  Two studies of people with HIV in Rakai, Uganda and Mombasa, Kenya presented at the 19th Conference on Retroviruses and Opportunistic Infections show that the rate at which they acquired second, subsequent strains of HIV was about the same ...

  10 March 2012 | Gus Cairns

• US CDC recommends HPV vaccine for young men

  Young men and adolescent boys between the ages of 11 and 21 should be vaccinated against human papillomavirus, the cause of genital warts, anal and cervical cancer, the Advisory Committee on Immunization Practices has recommended, in a new Adult ...

  06 February 2012 | Keith Alcorn

• Vaccine provides strong protection against HIV-like infection in monkeys

  A new vaccine approach provided monkeys with a high level of protection against a virulent form of SIV, the monkey equivalent of HIV. Vaccine researchers say the findings are promising, and provide important pointers on how to design an ...

  06 January 2012 | Keith Alcorn

• New vaccine against pneumococcal disease approved for UK

  A new vaccine that may be more suitable for preventing pneumococcal disease in people living with HIV has been approved in the United Kingdom. Prevenar 13, manufactured by Pfizer, is targeted at 13 variants of Streptococcus pneumoniae. Recently published research ...

  30 November 2011 | Keith Alcorn

• Immunisation doesn't prevent mother-to-child HIV transmissions, but approach should not be abandoned, says expert

  An experimental immunisation does not confer any addition protection against mother-to-child transmission of HIV compared to single-dose nevirapine, investigators report in the December 1st edition of the Journal of Acquired Immune Deficiency Syndromes.    The phase III, randomised study was conducted ...

  15 November 2011 | Michael Carter

More news

Vaccines news selected from other sources

• HIV inner shell structure revealed

  Researchers have for the first time unravelled the complex structure of the inner protein shell of the HIV molecule.

  30 May 2013 | BBC Health

• 'Gap' for HIV vaccine efforts after latest setback

  The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.

  20 May 2013 | FRANCE 24

• Competing antibodies may have limited the protection achieved in HIV vaccine trial in Thailand

  Continuing analysis of an HIV vaccine trial undertaken in Thailand is yielding additional information about how immune responses were triggered and why the vaccine did not protect more people.

  17 May 2013 | Eurekalert Inf Dis

• Cancer Vaccines Get a Price Cut in Poor Nations

  The two companies that make vaccines against cervical cancer announced Thursday that they would cut their prices to the world’s poorest countries below $5 per dose, eventually making it possible for millions of girls to be protected against a major deadly cancer.

  14 May 2013 | New York Times

• New tool for identifying powerful HIV antibodies

  A team of NIH scientists has developed a new tool to identify broadly neutralizing antibodies (bNAbs) capable of preventing infection by the majority of HIV strains found around the globe, an advance that could help speed HIV vaccine development.

  10 May 2013 | Science Daily

• AIDS vaccine trial results, while disappointing, must guide continuing search

  "This trial has provided a clear, swift answer about a specific vaccine strategy. It's not the answer we hoped for, but the search doesn't end here. There are other approaches that must be pursued without delay, and this result will help to focus and guide research efforts," said Mitchell Warren, AVAC executive director.

  26 April 2013 | AVAC press release

• NIH Discontinues Immunizations in HIV Vaccine Study

  The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will stop administering injections in its HVTN 505 clinical trial of an investigational HIV vaccine regimen because an independent data and safety monitoring board (DSMB) found during a scheduled interim review that the vaccine regimen did not prevent HIV infection nor reduce viral load (the amount of HIV in the blood) among vaccine recipients who became infected with HIV.

  25 April 2013 | National Institute of Allergy and Infectious Diseases (NIAID) press release

• HPV Vaccine Showing Successes in Australia

  The US government’s goal of vaccinating young girls against the human papillomavirus has been disappointing, with less than a third of teenagers having completed a full course of HPV vaccine. But now the United States can look to Australia, which six years into a successful nationwide HPV vaccination campaign has experienced a sharp decline in the number of new cases of genital warts among young men and women.

  19 April 2013 | New York Times

• Study Points to Possible Path to AIDS Vaccine

  In what may be an important step toward a long-elusive AIDS vaccine, American researchers have minutely tracked one person’s powerful immune response to the virus to see how a series of mutations led to an antibody that can defeat many H.I.V. strains. A vaccine still remains far off, but the research lighted up one complex path that may someday be followed to that distant goal.

  04 April 2013 | New York Times

• Researchers see antibody evolve against HIV

  For the first time, scientists have tracked in a patient the evolution of a potent immune molecule that recognizes many different HIV viruses. By revealing how these molecules — called broadly neutralizing antibodies — develop, the research could inform efforts to make vaccines that elicit similar antibodies that can protect people from becoming infected with HIV.

  04 April 2013 | Nature

More news